A carregar...
Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns
Immunotherapy combinations are used to improve outcomes in metastatic cancer, but evidence-based knowledge of appropriate starting doses for novel combinations is lacking. Phase I-III adult combination clinical trials (≥ 1 drug was immunotherapy; anti-PD-1, PD-L1, or CTLA-4) were reviewed (PubMed Ja...
Na minha lista:
| Publicado no: | Oncoimmunology |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5593707/ https://ncbi.nlm.nih.gov/pubmed/28920006 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1338997 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|